Philip Schauer, MD

The results of the "IFSO Survey: Use of Large Language Models (LLMs) by Metabolic Bariatric Surgeons and Integrated Health Professionals" have been published in Obesity Surgery Journal. Discover the key findings and insights here: rdcu.be/e8ogE

I’ll be there! How about you! @JaimePonceMD @Jmortonmd @metabolic_knife @NeilFlochMD @marinakurian @Ali_Aminian_MD @CorcellesMd @CarlosSchi398 @ASMBS @IfsoSecretariat

Thank you to Dr. Tim Allerton, for presenting his work in the Vascular Metabolism Laboratory at last week’s Work In Progress! #WIP

I'm on the faculty at the 2026 @ObesityAction Your Weight Matters National Convention in Orlando. My talk: "Obesity Treatments: What's New, What's Exciting, and What's on the Horizon." We're going to cover what's actually working right now, what's in the pipeline, and why the next 3-5 years in obesity medicine are unlike anything we've seen before. July 23–25 | Orlando, FL ywmconvention.com #ad #ObesityMedicine #YWMConvention

✏️ Hear from Dr. Donna Ryan of @PBRCNews as she gives her insights on the topline results released by @Roche on petrelintide. Read the full story ⬇️ #obesity vist.ly/4uus9

Three Presidents of The Obesity Society (TOS), representing more than four decades of leadership, gathered to celebrate the visit of TOS CEO Sherlyn Celone-Arnold. Presidents from 1991 (Claude Bouchard), 2006 (Eric Ravussin), and 2026 (Jackie Stephens).

Good points @Jmortonmd ! Also for bariatric surgery 1) when greater wt loss (> 30% TBWL) required (BMI > 40) 2) when cost is important ($1000 per year for 20 years). Having both options; medications AND surgery is best. @ObesitySociety @ObesityAction @ASMBS @NeilFlochMD

paper points out known facts- glp1s are up and bariatric surgery down- we can peacefully co-exist as valid, proven therapies-bariatric surgery will continue because patients: 1. May not have medication access 2. Don’t want long term medication 3. May not tolerate glp1s (10%) 4. May not respond to glp1s (5-10%) 5. See that bariatric works long term w 50% mortality reduction - at integrated centers we have not seen significant declines yalemedicine.org/departments/ce… future is to work together jamanetwork.com/journals/jama/…

Today, we’re celebrating the incredible Registered Dietitians who help make healthier living possible — including those right here at our center. 💙 Your dedication, expertise, and compassion inspire us every day. Thank you for all that you do for Pennington Biomedical! #NationalRegisteredDietitianDay #ThankYouDietitians #PenningtonProud #PBRCfam

Advancing children’s health at the Louisiana State Capitol! Dr. Katie Queen presented at the Children’s Cabinet meeting, representing LOS and @MyLAAAP, contributing to statewide discussions focused on improving access to comprehensive obesity care for children and families.

Today is World Obesity Day! Obesity isn’t an individual choice. It’s shaped by the systems around us. It’s time to stop the blame, understand the wider causes, and start changing the systems. 8 Billion Reasons to Act on Obesity – Share your Reason now. #WorldObesityDay

As Obesity Care Week ends, join us at ObesityWeek® 2026 in D.C., Nov 14–17! 🎓 Save $100 on 2025 OnDemand with code ObesityCare. 🔗 ow.ly/OozO50YmFBn #ObesityCareWeek #ObesityWeek26 #ObesityScience #ContinuingEducation

There are TEN days left to lock in early bird pricing for the premier event in metabolic and bariatric surgery. Register today and join us in just 58 days in San Antonio; because when we gather at #ASMBS2026, there will be No One Left Behind: asmbsmeeting.com #ASMBS2026

As #ObesityCareWeek comes to an end, let this week be your reminder that obesity affects us all. Whether it is for your child, your community, your health, or your hope for a better, fairer world, together we can combat the root causes of obesity to make a healthier future.

1 DAY LEFT until the 26th Annual Wellness Day for Women! This event is totally FREE and happening tomorrow March 7 from 7AM - 1PM. Registration is available online and in person! Visit pbrc.edu/wdw

Dr. Marina Kurian reminds us: obesity is a chronic disease, not a lack of willpower. She tailors care, medications, surgery, or both, based on each patient’s history. The first step? Make the appointment and start the conversation #MBS #IFSO

At LSU, we are committed to solving problems and discovering breakthroughs that benefit the people of Louisiana and the world. The researchers at @PBRCNews are the heart of that mission.

Pennington Biomedical's Pediatric Obesity & Health Behavior Laboratory promotes physical activity through "exergaming" and wearable technologies sciencex.com/wire-news/4501… #obesity #LSUResearch #ScholarshipFirst

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that blocks activin signaling pathways, results in greater weight loss while also preserving lean mass, such as skeletal muscle and connective tissue. In the paper “Bimagrumab and semaglutide alone or in combination for the treatment of obesity: a phase 2 randomized clinical trial,” published Monday in the journal Nature Medicine, Dr. Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies. To view the full article, visit pbrc.edu/news/media/202…